TNFalfa Blocking Treatment of Spondylarthropathies
- Sponsor
- Hvidovre University Hospital
- Study ID
- NCT00133315
- Phase
- PHASE4
- Status
- Completed
Conditions
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Spondylarthropathies
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Infliximab — DRUG
- Etanercept — DRUG
- Adalimumab — DRUG
Study Details
The purpose of the study is to establish a Danish cohort of spondylarthropathy (SpA) patients who are being treated with TNFalfa blockers. By following the TNFalfa blocking treated patients the researchers want to identify better biomarkers for disease activity and disease progression. In addition, the researchers want to identify predictors for disease progression.
Key Dates
- Start date
- Sep 30, 2004
- Status verified
- Apr 2007
- Completion
- Apr 30, 2007
Study Design
- Enrollment
- 50 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Rheumatology Patient Registry and BiorepositoryRecruiting · Yale University · New Haven, Connecticut
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas